Cadila Healthcare says FDA inspection at Ahmedabad facility had no observations

FDA
Recent FDA inspection finds no observations of of Indian drugmaker Cadila Healthcare's topical manufacturing facility at Changodar, Ahmedabad. (FDA)

Indian drugmaker Cadila Healthcare said a recent FDA inspection of its topical manufacturing facility at Changodar, Ahmedabad, resulted in no observations from the regulatory agency.

The inspection was conducted from March 22 through Wednesday. Of the 10 ANDA approvals the company has received from the FDA between 2016 and 2017, one was its first topical product approval for the formulations plant located in Ahmedabad. 

In late 2016, the company’s Moraiya plant, which is a formulation site, was one of two Cadila facilities in Gujarat to get warning letters the same month.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In those warning letters from the FDA, inspectors said they had serious concerns about Cadila's production of warfarin products following inspections in 2014. According to the agency, at least 5 batches fell short of expectations, but the drugmaker never uncovered the root cause so that it could be fixed.

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality control systems.